Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6412 participants.

Also called NCT04078737

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 6,412 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04078737
Other papers using this trial's data
  • Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial JAMA network open, 2023-06-01 DOI, PubMed 37279000, PMC10245195 In the PMC Open Access subset under CC BY.
  • Differential Effect of Ticagrelor Versus Clopidogrel by Causative Classification of Stroke Classification and Vascular Cellular Adhesion Molecule-1 Level on the Risk of Recurrent Stroke: A Post Hoc Analysis of the CHANCE-2 Trial Journal of the American Heart Association, 2026-01-06 DOI, PubMed 41413755, PMC12909013 In the PMC Open Access subset under CC BY-NC-ND.
  • Differential effect of ticagrelor versus clopidogrel by homocysteine levels on risk of recurrent stroke: a post hoc analysis of the CHANCE-2 trial CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2024-02-11 DOI, PubMed 38346785, PMC10861269 In the PMC Open Access subset under CC BY-NC-ND.
  • Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial Stroke, 2024-07 DOI, PubMed 38860396
  • Dual antiplatelet therapy with ticagrelor vs clopidogrel in patients with TIA or minor stroke with or without symptomatic carotid artery stenosis: a post hoc analysis of the CHANCE-2 trial Stroke and vascular neurology, 2025-10-27 DOI, PubMed 39773886, PMC12573349 In the PMC Open Access subset under CC BY-NC.
  • Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack Stroke, 2022-09 DOI, PubMed 35656824
  • Effect of insulin resistance on ticagrelor-versus clopidogrel-based dual antiplatelet therapy for secondary prevention of stroke in carriers of CYP2C19 loss-of-function mutations CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2026-01-18 DOI, PubMed 41554550, PMC12826683 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial Stroke and vascular neurology, 2024-11-05 DOI, PubMed 38286485, PMC11732837 In the PMC Open Access subset under CC BY-NC.
  • Genotype-guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE-2 Diabetes, obesity & metabolism, 2026-01 DOI, PubMed 41145384
  • Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2023-07-10 DOI, PubMed 37429630, PMC10446134 In the PMC Open Access subset under CC BY-NC-ND.
  • Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack Stroke, 2026-04 DOI, PubMed 41527826, PMC13003939 In the PMC Open Access subset under CC BY-NC-ND.
  • One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial Neurology, 2024-02-13 DOI, PubMed 38181311
  • PCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial Stroke, 2025-12 DOI, PubMed 40927840
  • Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack Stroke, 2023-04 DOI, PubMed 36789773
  • Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE-2 Journal of the American Heart Association, 2023-11-07 DOI, PubMed 37889172, PMC10727397 In the PMC Open Access subset under CC BY-NC-ND.
  • Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA The New England journal of medicine, 2021-12-30 DOI, PubMed 34708996
  • Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among CYP2C19 Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial Annals of internal medicine, 2022-11 DOI, PubMed 36315949

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04078737. Randomized; quadruple masking; primary purpose prevention. Start 2019-09-23 (actual); primary completion 2021-06-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
Acronym
CHANCE-2
Condition
Stroke
Intervention (Drug)
Ticagrelor and Aspirin
Intervention (Drug)
Clopidogrel and Aspirin
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Ministry of Science and Technology of the People´s Republic of China (class: other government)

Record details

Record id
cardio:ct-nct04078737
Content hash
68dcab0183f2ea1c09d407c133545aaf61714ee4ed4a707ccbf3501b94ca58f5